AF
IMDX

Amalgamated Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Amalgamated Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$14K Buy
+457
New +$14.6K ﹤0.01% 2832

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Amalgamated Financial's IMDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2022: 457 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2832 among its holdings.

86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Amalgamated Financial held 457 shares of Insight Molecular Diagnostics worth $14K as of Q1 2022.
  • Insight Molecular Diagnostics was a new Amalgamated Financial position in Q1 2022.
  • Insight Molecular Diagnostics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2832 holding.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.